Evidence map›Paper›PMID 34292474›Full record

Trial reportNeurocritical care2022

Intensive Blood Pressure Lowering and DWI Lesions in Intracerebral Hemorrhage: Exploratory Analysis of the ATACH-2 Randomized Trial.

Ashkan Shoamanesh, Christy Cassarly, Andrea Morotti, Javier M Romero, Jamary Oliveira-Filho, Frieder Schlunk, Michael Jessel, Kenneth Butcher, Laura Gioia, Alison Ayres and 9 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Neurocritical care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01176565 (Antihypertensive Treatment of Acute Cerebral Hemorrhage), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01176565 phase3terminatednot on this map

Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH)-II: A Phase III Randomized Multicenter Clinical Trial of Blood Pressure Reduction for Hypertension in Acute Intracerebral Hemorrhage

TypeinterventionalSponsorUniversity of MinnesotaRan2011 to 2016Enrolled1,000ConditionsIntracerebral HemorrhageArmsIntravenous nicardipine hydrochloride
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Observational
  3. Observational
  4. Review
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 4 countries.

Ashkan ShoamaneshDivision of Neurology, Department of Medicine, McMaster University / Population Health Research Institute, Hamilton, ON, Canada. ashkan.shoamanesh@phri.ca.ORCID http://orcid.org/0000-0002-2802-1626
Christy CassarlyDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.
Andrea MorottiStroke Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation, Pavia, Italy.
Javier M RomeroDepartment of Neurology J. P. Kistler Stroke Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Jamary Oliveira-FilhoDepartment of Neurology J. P. Kistler Stroke Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Frieder SchlunkDepartment of Neurology J. P. Kistler Stroke Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Michael JesselDepartment of Neurology J. P. Kistler Stroke Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Kenneth ButcherDepartment of Neurology, University of South Wales, Sydney, Australia.
Laura GioiaDepartment of Neurology, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada.
Alison AyresDepartment of Neurology J. P. Kistler Stroke Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Anastasia VashkevichDepartment of Neurology J. P. Kistler Stroke Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Kristin SchwabDepartment of Neurology J. P. Kistler Stroke Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Mohammad Rauf AfzalZeenat Qureshi Stroke Research Center, University of Minnesota, Minneapolis, MN, USA.
Renee H MartinDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.
Adnan I QureshiZeenat Qureshi Stroke Research Center, University of Minnesota, Minneapolis, MN, USA.
Steven M GreenbergDepartment of Neurology J. P. Kistler Stroke Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Jonathan RosandDepartment of Neurology J. P. Kistler Stroke Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Joshua N GoldsteinDepartment of Neurology J. P. Kistler Stroke Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
ATACH-2 and NETT investigators
Harvard University · USMedical University of South Carolina · USUniversity of Minnesota · USCentre Hospitalier de l’Université de Montréal · CAIstituti di Ricovero e Cura a Carattere Scientifico · ITPopulation Health Research Institute · CAUNSW Sydney · AU

Funding

Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-II)U01NS062091 · NINDS · UNIVERSITY OF MINNESOTA · PI QURESHI, ADNAN IQBAL · 2010 to 2014
$18.1M
SCORE-IT: The CTA Spot Sign Score in Acute Cerebral HemorrhageR01NS073344 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI ROSAND, JONATHAN · 2011 to 2015
$2.2M
NINDS NIH HHS R01 NS073344NINDS NIH HHS U01 NS062091
6 · The paper itself

Abstract

backgroundWith the increasing use of magnetic resonance imaging in the assessment of acute intracerebral hemorrhage, diffusion-weighted imaging hyperintense lesions have been recognized to occur at sites remote to the hematoma in up to 40% of patients. We investigated whether blood pressure reduction was associated with diffusion-weighted imaging hyperintense lesions in acute intracerebral hemorrhage and whether such lesions are associated with worse clinical outcomes by analyzing imaging data from a randomized trial.

methodsWe performed exploratory subgroup analyses in an open-label randomized trial that investigated acute blood pressure lowering in 1000 patients with intracerebral hemorrhage between May 2011 and September 2015. Eligible participants were assigned to an intensive systolic blood pressure target of 110-139 mm Hg versus 140-179 mm Hg with the use of intravenous nicardipine. Of these, 171 patients had requisite magnetic resonance imaging sequences for inclusion in these subgroup analyses. The primary outcome was the presence of diffusion-weighted imaging hyperintense lesions. Secondary outcomes included death or disability and serious adverse event at 90 days.

resultsDiffusion-weighted imaging hyperintense lesions were present in 25% of patients (mean age 62 years). Hematoma volume > 30 cm

conclusionsRandomized assignment to intensive acute blood pressure lowering did not result in a greater frequency of diffusion-weighted imaging hyperintense lesion. Alternative mechanisms of diffusion-weighted imaging hyperintense lesion formation other than hemodynamic fluctuations need to be explored. Clinical trial registration ClinicalTrials.gov (Ref. NCT01176565; https://clinicaltrials.gov/ct2/show/NCT01176565 ).

Indexed as

Antihypertensive AgentsCerebral HemorrhageBlood PressureHumansMiddle AgedNicardipineTreatment OutcomeAntihypertensive AgentsNicardipineDiffusion-weighted imagingIntracerebral hemorrhageMicroinfarcts

Identifiers

PMID34292474
OpenAlexW3184650394

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.